Predictive Oncology Inc ( (POAI) ) has released its Q2 earnings. Here is a breakdown of the information Predictive Oncology Inc presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Predictive Oncology Inc. is a company that leverages artificial intelligence and a proprietary biobank of over 150,000 tumor samples to enhance oncology drug discovery and development, aiming to improve cancer treatment outcomes. In its latest earnings report for the quarter ending June 30, 2025, Predictive Oncology highlighted a significant decrease in total assets from $4.97 million at the end of 2024 to $3.44 million, alongside a substantial net loss of $4.51 million for the first half of 2025. The company’s revenue for the same period was $112,992, a slight increase from the previous year, but operating expenses remained high, leading to continued losses. The company is facing financial challenges, including a stockholders’ deficit of $1.65 million and ongoing concerns about its ability to continue as a going concern without additional capital. Despite these challenges, Predictive Oncology is actively exploring various funding options to sustain operations and meet Nasdaq’s listing requirements, with a recent extension granted to demonstrate compliance by December 2025.